Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson(Royal Marsden Hospital), Jaap Verweij(Erasmus MC Cancer Institute), Hans Gelderblom(Leiden University Medical Center), Jörg T. Hartmann(University of Tübingen), Patrick Schöffski(KU Leuven), Jean‐Yves Blay(Centre Léon Bérard), J. Martijn Kerst(The Netherlands Cancer Institute), Josef Sufliarsky(National Institute of Cardiovascular Diseases), Jeremy Whelan(University College London), Peter Hohenberger(University Hospital Heidelberg), Anders Krarup‐Hansen(Herlev Hospital), Thierry Alcindor(McGill University), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Saskia Litière(European Organisation for Research and Treatment of Cancer), C. Hermans(European Organisation for Research and Treatment of Cancer), Cyril Fisher(Royal Marsden Hospital), Pancras C.W. Hogendoorn(Leiden University Medical Center), Angelo Paolo Dei Tos(Azienda ULSS 9 TREVISO), Winette T.A. van der Graaf(Radboud University Medical Center)
The Lancet Oncology
March 5, 2014
10.1016/s1470-2045(14)70063-4
Cited by 1,164Open Access
Full Text

Abstract

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al.|The Lancet|2012|2.1k
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel et al.|Journal of Clinical Oncology|2007|731
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis et al.|Journal of Clinical Oncology|1999|569
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
J H Edmonson, Louise Ryan, Ronald H. Blum et al.|Journal of Clinical Oncology|1993|518
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Karen H. Antman, John Crowley, S P Balcerzak et al.|Journal of Clinical Oncology|1993|481